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INTRODUCTION
Sodium-glucose transporter 2 (SGLT2) inhibitors have been
recently developed as oral hypoglycemic drugs for type 2 diabetes
mellitus that prevent the reabsorption of glucose from primary
urine at the proximal renal tubules by targeting SGLT2 (1-3).
Therapy with these medicines offers us multiphasic effects attrib-
utable to weight loss including improvement of insulin resistance,
reduction in blood pressure, dyslipidemia, and nonalcoholic fatty
liver disease (4). Their unique extra-pancreatic glucuretic mode
of action has encouraged their usage in type 1 diabetes as well (5).
The favorable clinical profile of SGLT2 inhibitors has increased
an interest in these medicines by health care providers. Especially
in Asian patients with glycated haemoglobin (HbA1c)8.5%, body
mass index (BMI)30.0, and65 years old, stratified analyses
of EMPA-REG OUTCOME study have indicated that SGLT2 in-
hibitors are more effective than other medicines (6). Six SGLT2
inhibitors (dapagliflozin, tofogliflozin, empagliflozin, ipragliflozin,
canagliflozin, and luseogliflozin) are now available in Japan, al-
though the cost of these medicines are relatively high because
they were recently developed. Since the medication with these
medicines promotes glucosuria, it may cause a greater incidence
of urinary tract infections, genital mycotic infections in female pa-
tients and sepsis of urinary origin (7, 8). Empagliflozin has the
highest selectivity for SGLT2 over SGLT1 (2,500- fold) compared
with other SGLT2 inhibitors (1,875- fold in tofogliflozin,1,200-
fold in dapagliflozin,550-fold in ipragliflozin and250-fold in
canagliflozin) (9). Since the terminal elimination half - life (t1/2) of
empagliflozin up to 13.1 hours (10), it is effective by one admini-
stration in a day. These facts give us a hypothesis that the admini-
stration of empagliflozin every other day might improve glycemic
control in patients with type 2 diabetes mellitus, not being inferior
to the therapy every day. Many reports have been published that
the use of SGLT2 inhibitors for long time are safe, efficacy and cost-
effective as a primary treatment or in combination with conven-
tional therapies (11, 12). However, there were no reports shown
whether continuous administration of low-dose empagliflozin of-
fers a sustainable benefit to patients with type 2 diabetes mellitus
after discontinuation of the treatment with other medicines or
changing the medication interval. Thus, the objective of this pilot
study is to investigate the sustainable effectiveness and safety of
10-mg every other day empagliflozin, comparing to results of 10-
mg every day empagliflozin for 24 weeks beyond the treatment
period.
MATERIALS AND METHODS
Design Overview
We conducted a prospective, open- label pilot study by the sim-
ple alternate randomization under no restrictions at a single clinic
and investigated the clinical effects and safety of the addition of
empagliflozin every day or every other day to type 2 diabetic pa-
tients with a poor control in glycemia. We obtained informed con-
sent from patients for participation in this study, and the study was
performed according to the procedure approved by the ethical and
research committee of Tokushima Prefectural Kaifu Hospital. Pa-
tients were enrolled between February 2015 and January 2016 from
Naka-cho National Health Insurance Kito Clinic, Japan.
Setting and Participants
Japanese patients with type 2 diabetes mellitus aged 30-70 years
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old, who were in inappropriate control of blood glucose levels
(HbA1c6.2%) in spite of diet and exercise therapies or with other
hypoglycemic agents such as biguanides, sulfonylureas, piogli-
tazone, α -glucosidase inhibitors, insulin, glucagon- like peptide-1
(GLP-1) agonists, and/or dipeptidyl peptidase 4 (DPP-4) were
recruited from our outpatient clinic. Patients kept exercise and diet
therapy during the study like before. The prescribed hypoglyce-
mic medicines were not changed during the course of the study.
The exclusion criteria for the study entry were as follows : 1) pa-
tients with serious infection, pre- or postoperative condition, or
severe trauma ; 2) pregnancy, possible pregnancy, or lactating pa-
tients ; 3) moderate or severe renal impairments by estimated
glomerular filtrating ratio [mL/min/1.73 m2]50 mL/min, serum
creatinine level1.5 mg/dL in men or1.3 mg/dL in women ; 4)
alanine aminotransferase and/or aspartate aminotransferase lev-
els 2.5 - fold more than the upper limit of normal range ; 5) patients
diagnosed as having cancer ; 6) patients medicated with corticoster-
oids ; 7) having experienced symptoms of hypoglycemia ; 8) in
severely poor control or unstable state with ketoacidosis or with an
increase in HbA1c3% in the 12 weeks before screening ; 9) pres-
ence of a severe health problem not suitable for the study ; 10)
inability to participate in the study due to psychiatric or psycho-
social status as assessed by the investigators.
Assignment and Interventions
Subjects were divided into two groups ; one was treatment with
10 mg of empagliflozin every day (Group A), the other was 10 mg
of empagliflozin every other day (Group B).
Measurement of Baseline Characteristics and Clinical Indices
Baseline characteristics data were recorded at the enrollment
including : age, gender, past medical history, personal history,
family history, body mass index (BMI), disease course, etc. The
comparable study of multiple clinical indexes between the 2 groups
was made before and 8, 16, and 24 weeks after the treatment,
including hematocrit (Ht), systolic and diastolic blood pressures
(SBP/DBP), BMI, HbA1c, triglyceride (TG), high-density lipo-
protein cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), and uric acid (UA). Three to five milliliter of blood
samples were collected from the antecubital vein into fluoride
tubes containing sodium citrate and ethlene-diamine-tetraacetic
and or heparin for the analysis in spite of meal time. Blood pressure
was measured by automatic sphygmomanometer at each visit. The
measurement of blood pressure was performed in the same way
for all patients. The data of HbA1c was expressed as a National
Glycohemoglobin Standardization Program (NGSP) equivalent
value calculated by the following formula : HbA1c (NGSP value)
(%)=1.02HbA1c (Japan Diabetes Society value) (%)+0.25 (13).
Safety evaluation throughout the study included physical exami-
nation, taking medial history and recording of side effects. The
relation between the usage of empagliflozin and side effects was
investigated. The number of all patients with side effects such as
urinary tract infections, genital mycotic infections, tremor, anxiety,
nausea, palpitation, hyperhidrosis, hunger and headache, adverse
drug reactions and serious side effects, and the incidence rates and
number of these events, were recorded.
Statistical Analysis
Data are shown as the meanstandard deviation and categorical
variables are expressed as percentages and data were analyzed
to identify any differences in HbA1c and other serum indices im-
provement. The differences in variables between the two different
treatment regimens were compared before and after the use of em-
pagliflozin. The data did not follow normal distribution and the data
were analyzed by non-parametric statistical methods. Intergroup
comparison was determined using the Mann-Whitney test. The in-
tragroup comparison was determined using the Wilcoxon signed
rank test. All statistical analyses were performed by StatView ver-
sion 5.0 (Abacus Concepts, Inc., Berkeley, CA) and P-values0.05
were considered statistically significant.
RESULTS
Baseline Characteristics of the Research Subjects
Thirteen Japanese patients diagnosed as type 2 diabetes mellitus
recruited to this study. Mean age was 52.88.4 years old and the
percentage of male was 76.9%. The patients were randomly divided
into the 2 groups. Twelve patients completed the treatment regi-
men, but a patient in group B dropped out of the study because of
adverse events. Group A consisted of 6 patients treated with 10 mg
of empagliflozin every day ; Group B consisted of 6 patients treated
with 10 mg of empagliflozin every other day. Table 1 shows the
baseline characteristics of patients in group A and Group B. No
significant difference was found between two groups in age, height,
weight, BMI, SBP, and DBP, and biochemical parameters includ-
ing Ht, HbA1c, TG, HDL, LDL, and UA, whereas AST and ALT
were significantly higher in group A than in group B. Hypoglyce-
mic agents which subjects used during the studied period are
shown in Table 2. After the treatment for 24 weeks, the HbA1c
level was decreased both in group A (from 7.5%1.1% to 6.5%
0.8%) and in group B (from 7.6%0.8% to 7.2%0.5%) when com-
pared with results at the baseline but there was no significant dif-
ference in both groups (Table 1, Fig. 1). Overall results in HbA1c
are shown in Fig. 4 in the Supplementary Appendix. A significantly
decreased TG was found in group A, but LDL tended to be in-
creased after the 24 weeks treatment in two groups (Table 1, Fig.
2, 3). Increased level of AST and ALT found in patients of Group
A at the baseline was decreased to normal range after 24 weeks
(Table 1). In Group B, there was no significant difference in TG
between baseline and week 24. The levels of HDL, LDL or TG at
24 weeks were not significantly different between the two groups
(Fig. 3). Overall results in LDL, HDL and TG are shown in Fig. 6
in the Supplementary Appendix.
SBP and DBP at 24 weeks were low when compared with those
at baseline, though there was not significant (Table 1, Fig. 2).
There was no significant difference in SBP and DBP at 24 weeks
between the two groups. Overall results in SBP and DBP also
tended to be decreased in Fig. 5 in the Supplementary Appendix.
Body weight and BMI were significantly decreased in 24 weeks
in group B though there was no significant difference in group A.
There was no significant difference in body weight and BMI at 24
weeks between the two groups (Table 1, Fig. 1).
Adverse Events
Adverse events were monitored throughout the study. Safety
and tolerability results are shown as follows : Overall, 4 (30.8%)
of the 13 subjects experienced AEs : two patients in group A (con-
stipation, pollakisuria, thirst) and 2 in group B (constipation, in-
somnia, pollakisuria). A total of 6 AEs were detected in these
subjects, 4 of which were mild and improved without treatment
before study end. A patient discontinued the treatment due to AEs.
Hypoglycemia was not detected in two groups. There were no
clinically related changes in laboratory dates, vital signs or ECG
recordings.
DISCUSSION
Empagliflozin is available as tablets (10 and 25 mg) and can only
be obtained with a prescription. The recommended starting dose
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is 10 mg once a day. In the present study, we examined that the
administration of 10 mg of empagliflozin every other day had the
availability and safety when compared with every day administra-
tion. Slightly but not significantly improved HbA1c level was seen
in the same extent in both groups after the treatment for 24 weeks.
No distinct differences in AEs were seen between the two groups
during this study.
There have been several previous reports showing that every
other day treatment with 20-mg tofogliflozin was used as add-on
treatment to patients with type 2 diabetes who were unable to
achieve adequate glycemic control. Takegoshi et al. reported that
the add-on treatment for 24 weeks decreased the level of HbA1c
to some extent (14, 15). These findings are compatible with results
in this study, indicating that 10-mg every other day empagliflozin
is potentially useful in improving glycemic control.
It has been showed that SGLT2 inhibitors including empagli-
flozin may improve other metabolic abnormalities, such as dyslipi-
demia, hyperuricemia and arterial hypertension (16-20). Our pilot
study had that a statistically significant decrease of TG from the
baseline was found with 10 mg of empagliflozin every day. These
lowering effect of SGLT2 inhibitors may be related to several
mechanisms, including improved glycemic control, decreases in
body weight, or other causes. In a few studies about the efficacy
of SGLT2 inhibitors on serum lipid profile, Matthaei et al. reported
that 52-week treatment of dapagliflozin significantly increased se-
rum HDL-C levels with no significant change of serum LDL-C and
TG levels (21). Monami et al. also showed that SGLT-2 inhibitors
significantly increased HDL-C levels with no change of TG and
LDL-C levels (22). In our pilot study, a tendency toward a decrease
in serum AST and ALT levels was observed at week 24 from base-
line in group A. Further studies will be needed to elucidate the
effects of SGLT2 inhibitors on improvement of hepatic steatosis
and liver function.
Systolic blood pressure also tended to be decreased after the
treatment in two groups. The mean changes in systolic blood pres-
sure were -16.8 mmHg in group A, and the other group was -17.3
mmHg.
Medication compliance and adherence is the essential relation
between prescribing a medication and treatment success and is
important in achieving maximum effectiveness for favorable out-
comes of prescribed regimens (23-25), but increasing the frequency
of medication and treatment cost could be barrier particularly in
Table 1. MeanSD of the variables assessed in the examined subjects
Group A (n=6) (empagliflozin 10 mg every day) Group B (n=6) (empagliflozin 10 mg every other day)
baseline 24 weeks later baseline 24 weeks later
Age (years) 51.5  10.5 52.0  10.7 53.9  6.7 54.4  6.6
BMI (kg/m2) 31.1  4.0 29.4  3.9 26.7  4.6 26.3  4.2*
Weight (kg) 81.2  11.2 78.3  11.2 70.4  17.0 70.1  15.8*
SBP (mmHg) 153.3  14.3 136.5  10.6 144.3  20.1 127.0  20.2
DBP (mmHg) 95.5  11.3 83.5  8.8 86.1  15.1 76.0  19.6
AST (IU/L) 53.7  24.5 43.8  20.4 26.7  6.3 27.7  9.4
ALT (IU/L) 72.3  35.0 52.0  33.6 26.4  10.3 23.0  9.2
Ht (%) 44.6  1.1 46.6  5.2 42.3  2.8 45.7  0.9
HbA1c (%) 7.5  1.1 6.5  0.8 7.6  0.8 7.2  0.5
TG (mg/dL) 190.8  121.7 99.6  33.7* 145.0  63.4 110.3  37.4
HDL (mg/dL) 44.0  8.3 54.8  17.9 49.9  16.6 50.5  9.9
LDL (mg/dL) 97.5  12.5 128.0  17.5 95.3  25.8 125.8  25.0
UA (mg/dL) 6.0  0.6 4.4  0.7 6.0  1.3 5.1  1.3
BMI, body mass index ; SBP, systolic blood pressure ; DBP, diastolic blood pressure ; AST, aspartate aminotransferase ; ALT, alanine aminotrans-
ferase ; Ht, hematocrit ; PG, plasma glucose ; TG, triglyceride ; HDL, high density lipoprotein cholesterol ; LDL, low density lipoprotein cholesterol ;
UA, uric acid
*p0.05 vs. baseline values. None of the intergroup differences reached statistical significance.
p0.05 vs. baseline values between empagliflozin 10 mg every day (Group A) versus every other day group (Group B) .
Table 2. Hypoglycemic agents which the subjects had taken before and after the treatment with empagliflozin
Medications
Group A Group B
baseline (n=6) 24 weeks later (n=6) baseline (n=7) 24 weeks later (n=6)
Biguanides 4 4 5 4
Thiazolidinediones 0 0 0 0
DPP-4 inhibitors 1 1 3 3
Sulfonylurea 0 0 0 0
α -GI 0 0 0 0
Glinides 1 1 4 3
GLP-1 analogues 1 1 0 0
Insulin 0 0 0 0
α -GI, alpha-glucosidase inhibitor ; DPP-4, dipeptidyl peptidase 4 ; GLP-1, glucagon- like peptide -1
52 F. Obata, et al. Comparison of treatment in patients
Fig. 1
Change in HbA1c (A), Body weight (B) and Ht (C) from baseline to 24 weeks. The data are presented as the mean values. The patients number
is 6 in group A (black circles) and 6 in group B (white circles).
*p0.05 vs. baseline values in each group. Group A consists of patients who received 10 mg of empagliflozin every day, and Group B consists of
patients who received 10 mg of empagliflozin every other day.
Fig. 2
Change in SBP (D), DBP (E) and UA (F) from baseline to 24 weeks. The data are presented as the mean values.
The patients number is 6 in group A (black circles) and 6 in group B (white circles).
*p0.05 vs. baseline values in each group. Group A consists of patients who received 10 mg of empagliflozin every day, and Group B consists of
patients who received 10 mg of empagliflozin every other day.
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Fig. 3
Change in LDL (G), HDL (H) and TG (I) from baseline to 24 weeks. The data are presented as the mean values.
The patients number is 6 in group A (black circles) and 6 in group B (white circles).
*p0.05 vs. baseline values in each group. Group A consists of patients who received 10 mg of empagliflozin every day, and Group B consists of
patients who received 10 mg of empagliflozin every other day.
Fig. 4
Overall results in HbA1c (A), Body weight (B) and Ht (C) from baseline to 24 weeks. The patients number is 6 in group A (circles) and 6 in group B
(triangles).
Group A consists of patients who received 10 mg of empagliflozin every day, and Group B consists of patients who received 10 mg of empagliflozin
every other day.
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Fig. 5
Overall results in SBP (D), DBP (E) and UA (F) from baseline to 24 weeks. The patients number is 6 in group A (circles) and 6 in group B (triangles).
Group A consists of patients who received 10 mg of empagliflozin every day, and Group B consists of patients who received 10 mg of empagliflozin
every otherday.
Fig.6
Overall results in LDL (G), HDL (H) and TG (I) from baseline to 24 weeks. The patients number is 6 in group A (circles) and 6 in group B (triangles).
Group A consists of patients who received 10 mg of empagliflozin every day, and Group B consists of patients who received 10 mg of empagliflozin
every otherday.
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low-income patients and may decrease patient compliance and
adherence (26). Regimen of long-term recommended treatment
among patients with a chronic disease has been showed that medi-
cation compliance may be as low as 50% (27) and in literature
reports, 20% to 50% of patients do not adhere to their prescribed
regimens, and the problem is more prominent in older adults, with
40% to 86% of elderly patients reported to be non-adherent (23, 25,
28), as they often use more medications, suffer a more number of
illnesses, and are at risk of age-related cognitive decline (24, 29).
In light of this, decreasing medication frequency may improve pa-
tient compliance and adherence. Taken together, the every other
day administration of empagliflozin may be a practical solution for
those patients with limited financial resources without compro-
mising the clinical benefits of HbA1c lowering and among patients
with previous empagliflozin intolerance.
The present study had several limitations. There was no placebo
or control group to compare with two groups that received treat-
ment. In addition, the duration of treatment was relatively short,
and the number of subjects was relatively small and insufficient.
Therefore, large-scale studies in which SGLT2 inhibitors are per-
formed to patients with type 2 diabetes mellitus for longer terms
should be need in the future.
CONCLUSIONS
In this small prospective, open- label pilot trial of empagliflozin
as a treatment in type 2 diabetes mellitus, every other day admini-
stration with 10 mg of empagliflozin was sufficiently effective in the
improvement of HbA1c and TG when compared with data of the
every day administration. This pilot trial suggested the possibility
of 10-mg every other day administration with empagliflozin for
Japanese patients with type 2 diabetes mellitus.
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